Patent · US Active

Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

US12351561B2 · kind B2 · utility

0Cited by

51References

63Claims

0Family size

Assignee

Theravance Biopharma R&D IP, LLC · US

Inventors

Adam D. Hughes · Rue de l'Église, US
Melissa Fleury · San Mateo, US
Miroslav Rapta · Redwood City, US
Venkat R. Thalladi · Foster City, US
R. Michael Baldwin · San Mateo, US
David L. Bourdet · Millbrae, US

Key dates

Filing date	Feb 15, 2024
Grant date	Jul 8, 2025
Priority date	—
Expiry date	Feb 15, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I′) forms.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.